- Home
- NUVL vs BBIO Comparison
NUVL vs BBIO Comparison
Compare NUVL & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- BBIO
- Stock Information
- Founded
- NUVL 2017
- BBIO 2015
- Country
- NUVL United States
- BBIO United States
- Employees
- NUVL N/A
- BBIO N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- NUVL Health Care
- BBIO Health Care
- Exchange
- NUVL Nasdaq
- BBIO Nasdaq
- Market Cap
- NUVL 5.6B
- BBIO 6.3B
- IPO Year
- NUVL 2021
- BBIO 2019
- Fundamental
- Price
- NUVL $70.46
- BBIO $34.62
- Analyst Decision
- NUVL Strong Buy
- BBIO Strong Buy
- Analyst Count
- NUVL 10
- BBIO 12
- Target Price
- NUVL $113.10
- BBIO $52.64
- AVG Volume (30 Days)
- NUVL 594.2K
- BBIO 2.7M
- Earning Date
- NUVL 05-08-2025
- BBIO 05-01-2025
- Dividend Yield
- NUVL N/A
- BBIO N/A
- EPS Growth
- NUVL N/A
- BBIO N/A
- EPS
- NUVL N/A
- BBIO N/A
- Revenue
- NUVL N/A
- BBIO $221,902,000.00
- Revenue This Year
- NUVL N/A
- BBIO $12.42
- Revenue Next Year
- NUVL N/A
- BBIO $123.19
- P/E Ratio
- NUVL N/A
- BBIO N/A
- Revenue Growth
- NUVL N/A
- BBIO 2285.27
- 52 Week Low
- NUVL $61.80
- BBIO $21.62
- 52 Week High
- NUVL $113.51
- BBIO $39.47
- Technical
- Relative Strength Index (RSI)
- NUVL 39.36
- BBIO 51.64
- Support Level
- NUVL $67.47
- BBIO $35.77
- Resistance Level
- NUVL $77.93
- BBIO $37.06
- Average True Range (ATR)
- NUVL 3.15
- BBIO 1.53
- MACD
- NUVL -0.44
- BBIO -0.03
- Stochastic Oscillator
- NUVL 26.88
- BBIO 48.45
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.